Protective Effect of Rivaroxaban Against Amyloid Pathology and Neuroinflammation Through Inhibiting PAR-1 and PAR-2 in Alzheimer’s Disease Mice
| Autor: | Zhihong, Bian, Xia, Liu, Tian, Feng, Haibo, Yu, Xiao, Hu, Xinran, Hu, Yuting, Bian, Hongming, Sun, Koh, Tadokoro, Mami, Takemoto, Taijun, Yunoki, Yumiko, Nakano, Yusuke, Fukui, Ryuta, Morihara, Koji, Abe, Toru, Yamashita |
|---|---|
| Rok vydání: | 2022 |
| Předmět: |
Amyloid beta-Peptides
General Neuroscience cerebral amyloid angiopathy chronic cerebral hypoperfusion Anticoagulants General Medicine warfarin Cerebral Amyloid Angiopathy Disease Models Animal Mice Psychiatry and Mental health Clinical Psychology Alzheimer Disease Neuroinflammatory Diseases Animals Humans Geriatrics and Gerontology Alzheimer’s disease rivaroxaban |
| Zdroj: | Journal of Alzheimer's Disease. 86:111-123 |
| ISSN: | 1875-8908 1387-2877 |
| DOI: | 10.3233/jad-215318 |
| Popis: | Background: Recent studies have revealed that atrial fibrillation (AF) patients have a high risk of developing cognitive impairment, vascular dementia, and Alzheimer’s disease (AD). Some reports suggest that the application of oral anticoagulant with an appropriate dose may have a preventive effect on AD. However, which oral anticoagulant drug is more appropriate for preventing AD and the underlying mechanism(s) is still unknown. Objective: The aim of the present study was to assess the treatment effect of rivaroxaban administration as well as investigate the roles of PAR-1 and PAR-2 in the AD + CAA mice model. Methods: In the present study, we compared a traditional oral anticoagulant, warfarin, and a direct oral anticoagulant (DOAC), rivaroxaban, via long-term administration to an AD with cerebral amyloid angiopathy (CAA) mice model. Results: Rivaroxaban treatment attenuated neuroinflammation, blood-brain barrier dysfunction, memory deficits, and amyloid-β deposition through PAR-1/PAR-2 inhibition in the AD + CAA mice model compared with warfarin and no-treatment groups. Conclusion: The present study demonstrates that rivaroxaban can attenuate AD progress and can be a potential choice to prevent AD. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|